Takeda Pharmaceutical (TYO:4502), through its subsidiary Millennium Pharmaceuticals, and Molecular Templates said today that the companies inked a deal to collaborate on an oncology drug discovery program.
The deal is slated to combine Molecular Templates’ engineered toxin bodies platform with therapeutic targets provided by Takeda.
Get the full story at our sister site, Drug Delivery Business News.
The post Takeda partners to develop novel oncology therapies appeared first on MassDevice.
from MassDevice http://ift.tt/2v5Svgb
Cap comentari:
Publica un comentari a l'entrada